Shots:

• The US FDA has issued a EUA for casirivimab (1-200mg) + imdevimab (1-200mg) administered together for mild to mod. COVID-19 in adults and pediatric patients aged ≥12yrs. weighing at least 40kg [~88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19
• The EUA is based on a P-II study that showed a reduction in hospitalization or ER visits in patients at high risk for disease progression within 28days after treatment and a reduction in viral loads
• Initial doses of Ab cocktail will be made available to ~300-000 patients- with no medication out-of-pocket costs- under the US government allocation program

 ­ Ref: Regeneron | Image: Fox Business